View Post

The Next-Generation Promise of ADCs and SERDs in Breast Cancer

In In The News by Barbara Jacoby

By: Lisa Astor From: targetedonc.com The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer. In 2022, development of novel targeted therapies has focused on antibody-drug conjugates (ADCs) and selective estrogen receptor degraders (SERDs). Both classes of agents have shown mixed efficacy over time. The generation in development offers reasons for excitement about improved …

View Post

Next-Generation Antibody-Drug Conjugates Make Their Mark in Breast Cancer

In In The News by Barbara Jacoby

By: Jane de Lartigue, PhD From: onclive.com In 2013, ado-trastuzumab emtansine (T-DM1; Kadcyla) gained FDA approval for the treatment of patients with HER2-positive metastatic breast cancer (MBC), making it the first antibody-drug conjugate (ADC) with an indication for a solid tumor. Since then, ADCs have become one of the fastest-growing classes of oncology drug therapy.1,2 In breast cancer, ADCs continue …

The Next Generation of “Patient-Centered”

In In The News by Barbara Jacoby

By Kameron Gifford, CPC Imagine a sustainable model of healthcare that could “touch” and engage every consumer. A system created for the patient and delivered on their own terms; a continually evolving structure that could simultaneously satisfy all the needs of patients, providers and payers. A design in which each stake holder adds value to the next.  This next generation …